The most important decision you'll make before starting a GLP-1
Before you pick a provider, before you compare prices, before you even decide between semaglutide and tirzepatide—you need to answer one question: brand-name or compounded? This decision affects your cost by hundreds of dollars a month, determines how your medication is regulated, and shapes your options if something goes wrong. It deserves more than a casual glance.
What "brand-name" actually means
Brand-name GLP-1 medications—Wegovy, Ozempic, Zepbound, Mounjaro—are manufactured by pharmaceutical companies (Novo Nordisk and Eli Lilly) under full FDA oversight. Every batch is tested for potency, sterility, and consistency. The manufacturing facilities undergo regular FDA inspections. The medications have been through Phase III clinical trials involving thousands of patients.
When you use Wegovy, you're getting the exact formulation that was tested in the STEP clinical trials. The dosing is standardized, the delivery device (pre-filled pen) is validated, and if something goes wrong, there's a clear chain of accountability.
What "compounded" actually means
Compounded GLP-1 medications contain the same active ingredients (semaglutide or tirzepatide) but are prepared by compounding pharmacies rather than the original manufacturer. These pharmacies mix the raw ingredient into injectable or oral formulations based on individual prescriptions.
There are two types of compounding pharmacies, and the distinction matters enormously:
503A pharmacies are state-licensed and compound medications on an individual prescription basis. They're regulated primarily by state boards of pharmacy and follow USP <797> guidelines. Quality control is less standardized—batch testing is sample-based, not mandatory for every batch.
503B outsourcing facilities are FDA-registered, federally inspected, and follow current Good Manufacturing Practices (cGMP). Every batch is tested for potency and sterility. This is meaningfully closer to brand-name quality control, though the formulations themselves are still not FDA-approved.
If you go the compounded route, a provider that sources from a 503B facility is the gold standard. Ask directly—reputable providers will name their pharmacy partner.
The regulatory landscape in 2026
This is where it gets complicated. The FDA ended the official semaglutide shortage on February 21, 2025, which triggered enforcement against 503A pharmacies that were compounding semaglutide without individual patient need. The 503A enforcement deadline was April 22, 2025, and the 503B deadline was May 22, 2025.
In practice, many compounding pharmacies continue to operate under various legal frameworks—some through patient-specific prescriptions that document clinical need (allergies, dosing requirements not met by commercial products), others through ongoing litigation. The tirzepatide shortage ended October 2, 2024, with 503B enforcement starting March 19, 2025.
The bottom line: compounded GLP-1 medications are still available through many telehealth providers in 2026, but the regulatory ground is shifting. Patients should understand that availability may change, and should always verify their provider's pharmacy credentials.
The cost gap: $149 vs. $1,349
Brand-name Wegovy carries a list price of approximately $1,349 per month. With NovoCare's cash-pay program, that drops to $349 per month ($199 for starter doses through June 2026). Zepbound ranges from $349 to $699 through LillyDirect. With commercial insurance and a manufacturer savings card, either can drop to as low as $25 per month.
Compounded semaglutide typically costs $149–$299 per month all-in, including medication, provider consultation, and shipping. Compounded tirzepatide runs $199–$399. No insurance is accepted or needed for compounded medications.
Over 12 months, the cost difference between brand-name (no insurance) and compounded can exceed $10,000. That's not a rounding error—it's a material financial decision for most people.
Quality and safety: what the data shows
The FDA has issued warning letters to several telehealth providers and compounding pharmacies for misleading claims, potency issues, and GMP violations. This is real and should be taken seriously. However, not all compounding pharmacies are equal—503B facilities with clean inspection records represent a dramatically different risk profile than a 503A pharmacy operating in a regulatory gray area.
Brand-name medications offer certainty: every pen contains exactly what the label says. Compounded medications introduce variability that depends entirely on the pharmacy producing them. This is why the "which pharmacy?" question is more important than the "brand vs. compounded?" question.
Who should choose brand-name
You should prioritize brand-name GLP-1 medications if your insurance covers them (even partially), if you want the strongest regulatory protections, if you have complex medical conditions requiring precise dosing, or if you're using GLP-1 specifically for cardiovascular risk reduction (SELECT trial data applies only to Wegovy).
Who should consider compounded
Compounded GLP-1 medications are a reasonable option if you're paying cash and brand-name is not financially sustainable, if your provider sources from a 503B outsourcing facility, if you need a dose or formulation not commercially available, or if brand-name medications are on backorder in your area.